Aytu BioPharma (AYTU) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Edesa Biotech (EDSA) over the past year, gaining 32.3% versus a gain of 17.6%. Over five years, AYTU leads with a -93.2% price change compared with -95.6% for EDSA. Aytu BioPharma is the larger company by market cap ($28.9 million vs $27.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | EDSA |
|---|---|---|
| Share price | $2.66 | $2.00 |
| Market cap | $28.91M | $27.02M |
| 1-day change | 0.00% | -8.05% |
| YTD return | +2.31% | +40.85% |
| 1-year return | +32.34% | +17.65% |
| 5-year return | -93.21% | -95.63% |
| Forward P/E | 17.16 | — |
| EPS (TTM) | $-1.78 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $57.57M | — |
| Revenue growth (YoY) | -13.27% | — |
| Net income (latest FY) | $-14.25M | $-7.19M |
| Gross margin | 63.95% | — |
| Operating margin | -14.44% | — |
| Net margin | -24.76% | — |
| 52-week high | $3.07 | $20.32 |
| 52-week low | $1.75 | $0.72 |
| Distance from 52-week high | -13.36% | -90.16% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +263.53% | +716.50% |
| Average volume | 141.18K | 1.45M |
| Shares outstanding | 10.87M | 13.51M |
| Employees | 75 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed EDSA by 14.7 percentage points over the past year.
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
AYTU vs EDSA FAQ
Which is bigger, Aytu BioPharma or Edesa Biotech?
Aytu BioPharma (AYTU) is larger, with a market capitalization of $28.91M compared with $27.02M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, AYTU or EDSA?
AYTU returned +32.34% over the past 12 months, compared with +17.65% for EDSA (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and Edesa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.